TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
08 Febbraio 2023 - 12:45PM
TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell
therapy company with a pipeline of novel T cell therapies for
patients suffering from solid tumors, today announced that
management will present a company update at the SVB Securities
Global Biopharma Conference (virtual) on Tuesday, February 14, 2023
at 1:00 PM ET.
A live webcast of the presentation will be
available on the Investors page of the Company’s website
at investors.tcr2.com. An archived replay will be available
for at least 30 days following the presentation.
About TCR² TherapeuticsTCR² Therapeutics
Inc. is a clinical-stage cell therapy company developing a
pipeline of novel T cell therapies for patients suffering from
solid tumors. The company is focused on the discovery and
development of product candidates against novel and complex targets
utilizing its proprietary T cell receptor (TCR) Fusion
Construct T cells (TRuC®-T cells). The TRuC platform is
designed to specifically recognize and kill cancer cells by
harnessing signaling from the entire TCR, independent of human
leukocyte antigens (HLA). For more information about TCR², please
visit www.tcr2.com.
Media Contact:Kathy
Vincentkathy@kathyvincent.com
Investor
Contact:Eric SullivanChief Financial
Officereric.sullivan@tcr2.com
Grafico Azioni TCR2 Therapeutics (NASDAQ:TCRR)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni TCR2 Therapeutics (NASDAQ:TCRR)
Storico
Da Set 2023 a Set 2024
Notizie in Tempo Reale relative a TCR2 Therapeutics Inc (NASDAQ): 0 articoli recenti
Più Articoli Notizie